Clinical trial · no report yet · Phase 3
VERITAC-3
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
- NCT05909397 ↗
- Active not recruiting
- Pfizer
- 9 commentary sources found
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| Podcasts | 5 | |
| YouTube | 4 |
The trial
ClinicalTrials.gov- Official title
- A PHASE 3, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY OF VEPDEGESTRANT (ARV-471/PF-07850327) PLUS PALBOCICLIB VERSUS LETROZOLE PLUS PALBOCICLIB FOR THE TREATMENT OF PARTICIPANTS WITH ESTROGEN RECEPTOR POSITIVE, HER2 NEGATIVE BREAST CANCER WHO HAVE NOT RECEIVED ANY PRIOR SYSTEMIC ANTI CANCER TREATMENT FOR ADVANCED DISEASE (VERITAC-3)
- Phase
- Phase 3
- Status
- Active not recruiting
- Conditions
- Breast Cancer
- Interventions
- Vepdegestrant (ARV-471/PF-07850327); Palbociclib; Letrozole; Palbociclib
- Arms
- Arm A (Investigational Arm) · Experimental
- Arm B (Comparator Arm): · Active comparator
- Enrollment
- 59
- Primary outcomes
- Study Lead-in (SLI): Incidence of Grade 4 neutropenia
- SLI: Incidence of dose reduction
- SLI: Incidence of drug discontinuation.
- Phase 3: Progression-Free Survival
- Sponsor
- Pfizer with Arvinas Estrogen Receptor, Inc.
- Start
- Aug 9, 2023
- Primary completion
- Dec 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT05909397 · updated Feb 10, 2026